Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of MANP in Resistant Hypertension
NCT05247528Phase 1Completed
- Sponsor
- E-Star BioTech
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in resistant hypertension (RH) comparing Placebo Comparator with MANP Experimental (2 arms). Primary endpoints: Adverse Events, Systolic and Diastolic Blood Pressure at Day 21 and 4 more. Started Dec 2021; status: completed.
02
Drugs
M-atrial natriuretic peptide
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT05247528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247528.